JP2018516950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516950A5 JP2018516950A5 JP2017563600A JP2017563600A JP2018516950A5 JP 2018516950 A5 JP2018516950 A5 JP 2018516950A5 JP 2017563600 A JP2017563600 A JP 2017563600A JP 2017563600 A JP2017563600 A JP 2017563600A JP 2018516950 A5 JP2018516950 A5 JP 2018516950A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- ifn
- molecule
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103895A JP2021167324A (ja) | 2015-06-12 | 2021-06-23 | がん治療のための集中インターフェロン免疫療法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175044P | 2015-06-12 | 2015-06-12 | |
| US201562175024P | 2015-06-12 | 2015-06-12 | |
| US62/175,024 | 2015-06-12 | ||
| US62/175,044 | 2015-06-12 | ||
| US201562257852P | 2015-11-20 | 2015-11-20 | |
| US62/257,852 | 2015-11-20 | ||
| US201662321724P | 2016-04-12 | 2016-04-12 | |
| US62/321,724 | 2016-04-12 | ||
| PCT/US2016/036925 WO2016201251A1 (en) | 2015-06-12 | 2016-06-10 | Focused interferon immunotherapy for treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103895A Division JP2021167324A (ja) | 2015-06-12 | 2021-06-23 | がん治療のための集中インターフェロン免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516950A JP2018516950A (ja) | 2018-06-28 |
| JP2018516950A5 true JP2018516950A5 (https=) | 2019-09-05 |
Family
ID=57504236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563600A Pending JP2018516950A (ja) | 2015-06-12 | 2016-06-10 | がん治療のための集中インターフェロン免疫療法 |
| JP2021103895A Pending JP2021167324A (ja) | 2015-06-12 | 2021-06-23 | がん治療のための集中インターフェロン免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103895A Pending JP2021167324A (ja) | 2015-06-12 | 2021-06-23 | がん治療のための集中インターフェロン免疫療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180312561A1 (https=) |
| EP (1) | EP3307301A4 (https=) |
| JP (2) | JP2018516950A (https=) |
| AU (2) | AU2016274897B2 (https=) |
| CA (1) | CA2988619A1 (https=) |
| WO (1) | WO2016201251A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110573172A (zh) * | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3577133A1 (en) * | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| CN109810995B (zh) * | 2017-12-06 | 2020-10-02 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
| CN110194800B (zh) * | 2018-02-26 | 2022-11-18 | 张灏 | 一种融合蛋白、细胞外泌体和肿瘤疫苗及其应用 |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| KR20220109436A (ko) | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | 인터페론-결합된 항원 결합 단백질 및 이의 용도 |
| CA3222185A1 (en) * | 2021-06-03 | 2022-12-08 | Orum Therapeutics, Inc. | Neodegrader-anti-cd33 antibody conjugates |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040001789A1 (en) * | 1999-10-08 | 2004-01-01 | Young David S. F. | Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof |
| ES2536772T3 (es) * | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| US9272029B2 (en) * | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
| ES2611479T3 (es) * | 2010-06-16 | 2017-05-09 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Anticuerpos contra endoplasmina y su uso |
| EP2718457A4 (en) * | 2011-06-06 | 2014-12-24 | Immungene Inc | GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT |
| SG10201603411WA (en) * | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| ES2800426T3 (es) * | 2012-03-03 | 2020-12-30 | Immungene Inc | Moléculas de fusión anticuerpos-mutante de interferón modificadas |
| EP2981281B1 (en) * | 2013-04-03 | 2020-07-15 | IBC Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
-
2016
- 2016-06-10 US US15/735,583 patent/US20180312561A1/en not_active Abandoned
- 2016-06-10 CA CA2988619A patent/CA2988619A1/en not_active Abandoned
- 2016-06-10 AU AU2016274897A patent/AU2016274897B2/en not_active Ceased
- 2016-06-10 EP EP16808391.3A patent/EP3307301A4/en not_active Withdrawn
- 2016-06-10 WO PCT/US2016/036925 patent/WO2016201251A1/en not_active Ceased
- 2016-06-10 JP JP2017563600A patent/JP2018516950A/ja active Pending
-
2021
- 2021-05-13 AU AU2021203042A patent/AU2021203042A1/en not_active Abandoned
- 2021-06-23 JP JP2021103895A patent/JP2021167324A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516950A5 (https=) | ||
| JP6966176B2 (ja) | ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体 | |
| CN108368179B (zh) | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 | |
| EP2970473B1 (en) | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use | |
| JP2021167324A5 (https=) | ||
| JP7274426B2 (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| US20180044428A1 (en) | Compositions and methods for enhancing the efficacy of cancer therapy | |
| HK1225634A1 (zh) | 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法 | |
| JP7606706B2 (ja) | ヒトネクチン－２に特異的な抗体 | |
| JP2014527814A5 (https=) | ||
| JP2020527332A5 (https=) | ||
| JP2019517505A (ja) | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ−１抗体の使用 | |
| JP7809635B2 (ja) | Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング | |
| US20230183342A1 (en) | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections | |
| CN113874036A (zh) | 使用cdk抑制剂的联合治疗 | |
| EP3893888A1 (en) | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist | |
| JP2021500320A (ja) | 癌の治療のための配合剤 | |
| EP4090430A1 (en) | Method of treating a tumor with a combination of il-7 protein and a bispecific antibody | |
| TW202313109A (zh) | 用抗ｃｄ３９抗體治療癌症之方法 | |
| RU2836467C2 (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
| JP2022527345A (ja) | Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法 | |
| HK40079353A (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| HK1259020B (en) | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |